0001415889-22-000715.txt : 20220121
0001415889-22-000715.hdr.sgml : 20220121
20220121204118
ACCESSION NUMBER: 0001415889-22-000715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220121
FILED AS OF DATE: 20220121
DATE AS OF CHANGE: 20220121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Guarino Jonathan L.
CENTRAL INDEX KEY: 0001787282
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14778
FILM NUMBER: 22547250
MAIL ADDRESS:
STREET 1: 100 WELLESLEY WAY
CITY: FREEHOLD
STATE: NJ
ZIP: 07728
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLIGENIX, INC.
CENTRAL INDEX KEY: 0000812796
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 411505029
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-538-8200
MAIL ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: DOR BIOPHARMA INC
DATE OF NAME CHANGE: 20020329
FORMER COMPANY:
FORMER CONFORMED NAME: ENDOREX CORP
DATE OF NAME CHANGE: 19960916
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19920703
4
1
form4-01212022_050109.xml
X0306
4
2022-01-21
0000812796
SOLIGENIX, INC.
SNGX
0001787282
Guarino Jonathan L.
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10
PRINCETON
NJ
08540
false
true
false
false
CHIEF FINANCIAL OFFICER
Option (Right to Buy)
0.78
2022-01-21
4
A
0
50000
0
A
2021-12-09
2031-12-08
Common Stock
50000
50000
D
The terms of the stock option provide that it is to vest immediately as to 12,500 shares and to vest as to the remainder at a rate of 3,125 of the shares every three months, beginning on March 12, 2022; provided, however, that, consistent with the 2015 Equity Incentive Plan (the "Plan") and the rules of the Nasdaq Stock Market, such stock option shall not be exercisable nor shall it vest prior to the time when an amendment increasing the number of shares authorized for issuance under the Plan is approved by the stockholders, and provided further that, if such approval has not been obtained within 12 months of the grant date, the stock option shall thereupon be canceled and become null and void. The reporting person voluntarily agreed to cancel the stock option granted December 9, 2021 with respect to 50,000 shares.
/s/ Jonathan L. Guarino
2022-01-21